Temporal trends in oropharyngeal cancer treatment and survival: 1998-2009

Laryngoscope

Volumn 124, Issue 1, 2014, Pages 131-138

  Chen, Amy Y ^a   Zhu, Jason ^b   Fedewa, Stacey ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Oropharyngeal cancer; patterns of care; survival; treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; SOCIAL STATUS; SQUAMOUS CELL CARCINOMA; TEACHING HOSPITAL; TUMOR INVASION; ADOLESCENT; MIDDLE AGED; MORTALITY; OROPHARYNGEAL NEOPLASMS; SURVIVAL RATE; TIME; YOUNG ADULT; OROPHARYNX TUMOR; PATTERNS OF CARE; SURVIVAL; TREATMENT;

ADOLESCENT; ADULT; AGED; CHEMORADIOTHERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

OROPHARYNGEAL CANCER; PATTERNS OF CARE; SURVIVAL; TREATMENT;

EID: 84895842411     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24296     Document Type: Article

References (46)

1. Warnakulasuriya S,. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-316.
2. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011. CA Cancer J Clin 2011; 61: 212-236.
3. D'Souza G, Kreimer AR, Viscidi R, et al. Case-Control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.
4. Syrjanen K, Syrjanen S, Lamberg M, Pyrhonen S, Nuutinen J,. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 1983; 12: 418-424.
5. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
6. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619.
7. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008; 113: 2901-2909.
8. Dahlstrom KR, Calzada G, Hanby JD, et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center. Cancer 2013; 119: 81-89.
9. Robinson KL, Macfarlane GJ,. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol 2003; 39: 31-36.
10. Scottish Intercollegiate Guidelines Network. Diagnosis and management of head and neck cancer 2006. Available at: http://www.sign.ac.uk/pdf/sign90.pdf. Accessed July 10, 2012.
11. NCCN clinical practice guidelines in oncology: head and neck cancers 2012. Available at: http://www.nccn.org/professionals/physician-gls/f- guidelines.asp#head-and-neck. Accessed July 10, 2012.
12. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
13. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
14. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086.
15. Chen AY, Schrag N, Hao Y, Stewart A, Ward E,. Changes in treatment of advanced oropharyngeal cancer, 1985-2001. Laryngoscope 2007; 117: 16-21.
16. National Cancer Database. Available at: http://www.facs.org/cancer/ncdb/ index.html. Accessed October 20, 2009.
17. Commission on Cancer. Facility oncology registry data standards (FORDS). Revised for 2007. Chicago, IL: American College of Surgeons; 2007.
18. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Handbook. 6th ed. New York, NY: Springer; 2002.
19. Kleinbaum DG,. Survival Analysis: A Self-Learning Text. New York, NY: Springer; 1996.
20. Annertz K, Anderson H, Biorklund A, et al. Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer 2002; 101: 95-99.
21. Conway DI, Stockton DL, Warnakulasuriya KAAS, Ogden G, Macpherson LMD,. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol 2006; 42: 586-592.
22. Schantz SP, Yu GP,. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg 2002; 128: 268-274.
23. Chen AY, Fedewa S, Zhu J,. Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007. Arch Otolaryngol Head Neck Surg 2011; 137: 1017-1024.
24. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000; 88: 876-883.
25. Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med 1988; 318: 612-617.
26. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP,. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 2000; 90: 1746-1754.
27. Lindley C, McCune JS, Thomason TE, et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 1999; 7: 59-65.
28. Oddone EZ, Horner RD, Diers T, et al. Understanding racial variation in the use of carotid endarterectomy: the role of aversion to surgery. J Natl Med Assoc 1998; 90: 25-33.
29. Skinner J, Weinstein JN, Sporer SM, Wennberg JE,. Racial, ethnic, and geographic disparities in rates of knee arthroplasty among Medicare patients. N Engl J Med 2003; 349: 1350-1359.
30. Bach PB, Cramer LD, Warren JL, Begg CB,. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341: 1198-1205.
31. Shavers VL, Harlan LC, Winn D, Davis WW,. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. Cancer Metastasis Rev 2003; 22: 25-38.
32. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26: 3582-3589.
33. Milet PR, Mallet Y, El Bedoui S, Penel N, Servent V, Lefebvre J-L,. Head and neck cancer surgery in the elderly-does age influence the postoperative course? Oral Oncol 2010; 46: 92-95.
34. Sesterhenn AM, Schotte TL, Bauhofer A, et al. Head and neck cancer surgery in the elderly: outcome evaluation with the Mcpeek score. Ann Otol Rhinol Laryngol 2011; 120: 110-115.
35. Arbes SJ Jr, Olshan AF, Caplan DJ, Schoenbach VJ, Slade GD, Symons MJ,. Factors contributing to the poorer survival of black americans diagnosed with oral cancer (United States). Cancer Causes Control 1999; 10: 513-523.
36. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
37. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
38. Chernock RD, Zhang Q, El-Mofty SK, Thorstad WL, Lewis JS Jr,. Human papillomavirus-related squamous cell carcinoma of the oropharynx: a comparative study in whites and African Americans. Arch Otolaryngol Head Neck Surg 2011; 137: 163-169.
39. Settle K, Posner MR, Schumaker LM, et al. Racial Survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009; 2: 776-781.
40. Kwok J, Langevin SM, Argiris A, Grandis JR, Gooding WE, Taioli E,. The impact of health insurance status on the survival of patients with head and neck cancer. Cancer 2010; 116: 476-485.
41. Pitchers M, Martin C,. Delay in referral of oropharyngeal squamous cell carcinoma to secondary care correlates with a more advanced stage at presentation, and is associated with poorer survival. Br J Cancer 2006; 94: 955-958.
42. Rogers SN, Harvey-Woodworth CN, Hare J, Leong P, Lowe D,. Patients' perception of the financial impact of head and neck cancer and the relationship to health related quality of life. Br J Oral Maxillofac Surg 2012; 50: 410-416.
43. Waaijer A, Terhaard CHJ, Dehnad H, et al. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol 2003; 66: 271-276.
44. Gorey KM, Luginaah IN, Holowaty EJ, Fung KY, Hamm C,. Wait times for surgical and adjuvant radiation treatment of breast cancer in Canada and the United States: greater socioeconomic inequity in America. Clin Invest Med 2009; 32: E239-E249.
45. Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY,. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol 2009; 99: 488-490.
46. Lohavanichbutr P, Houck J, Fan W, et al. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg 2009; 135: 180-188.